Factor seven activating protease (FSAP) is activated massively in multiple trauma patients and in turn activates complement factors

被引：0
|
作者：
Kanse, S. M. [1 ]
Gallenmueller, A. [2 ]
Krueger, M. [3 ]
Huber-Lang, M. [2 ]
机构：
[1] Univ Giessen, Inst Biochem, Bad Nauheim, Germany
[2] Univ Hosp Ulm, Dept Traumatol, Bad Nauheim, Germany
[3] Max Planck Inst, D-6350 Bad Nauheim, Germany
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2011年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：51 / 51
页数：1
相关论文
共 33 条
  • [21] Factor Seven Activating Protease (FSAP) counteracts vascular stenosis progression through cleavage of Platelet Derived Growth Factor (PDGF)-BB.
    Daniel, J-M.
    Hersemeyer, K.
    Schmidt-Woell, T.
    Kaetzel, D. N.
    Tillmans, H.
    Sedding, D. G.
    Kanse, S. M.
    CARDIOVASCULAR RESEARCH, 2010, 87 : S61 - S62
  • [22] Circulating Factor Seven Activating Protease (FSAP) is associated with clinical outcome in acute coronary syndrome, but not with complexity of coronary artery disease
    Parahuleva, M.
    Neuhof, C.
    Hoelschermann, H.
    Tillmanns, H.
    Erdogan, A.
    Kanse, S.
    EUROPEAN HEART JOURNAL, 2009, 30 : 149 - 149
  • [23] Macrophages and platelets are the major source of the Factor Seven Activating Protease (FSAP) in human atherosclerotic plaques: a possible crosslink between inflammation and coagulation
    Markus, B.
    Worsch, W.
    Parviz, B.
    Luesebrink, U.
    Schieffer, B.
    Kanse, S.
    Parahuleva, M.
    EUROPEAN HEART JOURNAL, 2014, 35 : 989 - 989
  • [24] Factor VII activating protease (FSAP) is not essential in the pathophysiology of angioedema in patients with C1 inhibitor deficiency
    Gramstad, Olav Rogde
    Kandanur, Sai Priya Sarma
    Etscheid, Michael
    Nielsen, Erik Waage
    Kanse, Sandip Mahadev
    MOLECULAR IMMUNOLOGY, 2022, 142 : 95 - 104
  • [25] Association of circulating factor seven activating protease (FSAP) and of oral Omega-3 fatty acids supplements with clinical outcome in patients with atrial fibrillation: the OMEGA-AF study
    Mariana S. Parahuleva
    Sandip Kanse
    Hans Hölschermann
    Kirila Zheleva
    Daniel Zandt
    Michael Worsch
    Behnoush Parviz
    Norbert Güttler
    Harald Tillmanns
    Andreas Böning
    Ali Erdogan
    Journal of Thrombosis and Thrombolysis, 2014, 37 : 317 - 325
  • [26] Association of circulating factor seven activating protease (FSAP) and of oral Omega-3 fatty acids supplements with clinical outcome in patients with atrial fibrillation: the OMEGA-AF study
    Parahuleva, Mariana S.
    Kanse, Sandip
    Hoelschermann, Hans
    Zheleva, Kirila
    Zandt, Daniel
    Worsch, Michael
    Parviz, Behnoush
    Guettler, Norbert
    Tillmanns, Harald
    Boening, Andreas
    Erdogan, Ali
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2014, 37 (03) : 317 - 325
  • [27] Low-dose recombinant activated factor VII in massively transfused trauma patients with coagulopathy
    Bauza, Graciela
    Hirsch, Erwin
    Burke, Peter
    Quillen, Karen
    TRANSFUSION, 2007, 47 (04) : 749 - 751
  • [28] Raised protein levels and altered cellular expression of factor VII activating protease (FSAP) in the lungs of patients with acute respiratory distress syndrome (ARDS)
    Wygrecka, Malgorzata
    Markart, Philipp
    Fink, Ludger
    Guenther, Andreas
    Preissner, Klaus T.
    THORAX, 2007, 62 (10) : 880 - 888
  • [29] Efficacy of low-dose recombinant activated factor VII (rFVIIa) in massively transfused trauma patients with coagulopathy
    Quillen, K
    Hirsch, E
    Bauza, G
    BLOOD, 2005, 106 (11) : 279A - 279A
  • [30] Single institution experience of recombinant activated factor VII (Novo-Seven) in the management of intractable bleeding in surgical and trauma patients.
    Alcorn, K
    Aggarwal, A
    BLOOD, 2002, 100 (11) : 91B - 91B
1234